Şengül, AysunMutlu, PinarÖzdemir, ÖzerSatıcı, CelalTuran, Muzaffer OnurArslan, SertaçOğan, Nalan2023-07-262023-07-2620221747-63481747-6356https://doi.org/10.1080/17476348.2022.2102480https://hdl.handle.net/20.500.12684/12448Background COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient's characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. Methods We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Results Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of >= 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Conclusion Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia.en10.1080/17476348.2022.2102480info:eu-repo/semantics/closedAccessCovid-19; Corticosteroid; Hypoxemia; Mortality; PrognosisRespiratory-Distress-Syndrome; Dexamethasone; SeverityArticle168953958358393452-s2.0-85135114550WOS:000831157700001N/AQ2